920304-57-0

Basic information

• Product Name: N,N-Diethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline
• Synonyms: 2-[4-(Diethylamino)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane;4-(Diethylamino)phenylboronic Acid Pinacol Ester;N,N-Diethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline;4-(Diethylamino)benzeneboronic acid, pinacol ester;2-[4-(Diethylamino)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 4-(Diethylamino)phenylboronic Acid Pinacol Ester;N,N-diethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenamine;N,N-Diethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline
• CAS NO: 920304-57-0
• Molecular Formula: C₁₆H₂₆BNO₂
• Molecular Weight: 275.19
• Product Categories: B (Classes of Boron Compounds);Boronic Acids Esters
• Mol File: 920304-57-0.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 377.028°C at 760 mmHg
• Flash Point: 181.82°C
• Appearance: /
• Density: 0.995g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.504
• Solubility: soluble in Methanol
• PKA: 6.23±0.44(Predicted)
• CAS DataBase Reference: N,N-Diethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline(CAS DataBase Reference)
• NIST Chemistry Reference: N,N-Diethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline(920304-57-0)
• EPA Substance Registry System: N,N-Diethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline(920304-57-0)

Safety Data

• Hazardous Substances Data: 920304-57-0(Hazardous Substances Data)

Usage

Description

N,N-Diethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline is a boronic acid derivative with the molecular formula C17H28BNO. It features an aniline group and a boron-containing heterocycle, making it a versatile and valuable intermediate in organic chemistry. This chemical compound is widely recognized for its role as a building block in the synthesis of complex organic molecules and pharmaceutical compounds.

Uses

Used in Organic Synthesis:
N,N-Diethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline is used as a building block in organic synthesis for the formation of complex organic molecules. Its unique structure allows for the creation of a variety of compounds with diverse properties and applications.
Used in Pharmaceutical Compounds:
In the pharmaceutical industry, N,N-Diethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline is utilized as a key intermediate in the synthesis of various pharmaceutical compounds. Its ability to form stable bonds with other molecules makes it an essential component in the development of new drugs.
Used in Material Development:
N,N-Diethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline has been studied for its potential application in the development of new materials. Its unique properties and reactivity make it a promising candidate for creating innovative materials with improved performance characteristics.
Used as a Catalyst in Organic Reactions:
In addition to its role as a building block, N,N-Diethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline is also considered for its potential use as a catalyst in organic reactions. Its ability to facilitate chemical transformations can enhance the efficiency and selectivity of various organic processes.

InChI:InChI=1/C16H26BNO2/c1-7-18(8-2)14-11-9-13(10-12-14)17-19-15(3,4)16(5,6)20-17/h9-12H,7-8H2,1-6H3

Upstream product

• 91-66-7 N,N-diethylaniline 
• 73183-34-3 bis(pinacol)diborane 
• 74-96-4 ethyl bromide 
• 214360-73-3 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)aniline 
• 75-03-6 ethyl iodide 

Downstream Products

• 1374109-34-8 C₂₈H₃₉FN₂O₂Si 
• 1374108-94-7 C₃₆H₃₈N₂O₃ 
• 1374108-61-8 C₂₃H₂₈N₂O₂ 
• 1374108-56-1 C₂₅H₃₀N₂O₃ 
• 1374108-53-8 C₂₉H₃₁FN₂O₂ 
• 1374108-50-5 C₂₉H₃₁FN₂O₂ 
• 1374108-44-7 C₂₆H₂₆N₂O 
• 1374108-42-5 C₂₉H₃₁FN₂O₂ 
• 1374108-38-9 C₂₆H₂₆N₂O 

Relevant articles and documents

Meta Selective C-H Borylation of Sterically Biased and Unbiased Substrates Directed by Electrostatic Interaction

An electrostatically directed meta borylation of sterically biased and unbiased substrates is described. The borylation follows an electrostatic interaction between the partially positive and negative charges between the ligand and substrate. With this strategy, it has been demonstrated that a wide number of challenging substrates, especially 4-substituted substrates, can selectively be borylated at the meta position. Moreover, unsubstituted substrates also displayed excellent meta selectivity. The reaction employs a bench-stable ligand and proceeds at a milder temperature, precluding the need to synthesize a bulky and sophisticated ligand/template.

PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH ZINC BINDING MOIETY

PROBLEM TO BE SOLVED: To provide phosphoinositide 3-kinase inhibitors with a zinc binding moiety. SOLUTION: There is provided a compound represented by formula (I) in the figure. (X is S, O or the like; Y is CH, N or the like; G1 is optionally substituted N or the like; R1 and R2 are each independently H or the like; C is a substituted heterocycle or the like; B is a linear alkyl or the like; Ra and Rb together with the nitrogen atom coupled to them are morpholino or the like; G2 is an indazole ring or the like; q, r and s are independently from 0 to 1, provided that at least one of them is 1; t is from 0 to 1; n is from 0 to 4; and p is from 0 to 2.) COPYRIGHT: (C)2016,JPOandINPIT

TREATMENT OF CANCERS HAVING K-RAS MUTATIONS

The present invention provides a method of treating a cancer associated with a K-ras mutation in a subject in need thereof. The method comprises the steps of: (1) identifying a subject with a cancer associated with a K-ras mutation; and (2) administering to the subject (i) an inhibitor of PI3 kinase and (ii) an HDAC inhibitor, wherein the PI3 kinase inhibitor and the HDAC inhibitor are administered in amounts which together are therapeutically effective.